Peer Review: Leaving Cerecor after a year, Peter Greenleaf starts a new CEO chapter at Aurinia — out to slay Restasis
→ A year after orchestrating Sucampo Pharma’s sale to Mallinckrodt, Peter Greenleaf is still in hot demand. Aurinia has poached him from the helm of Cerecor, where he’s helped lay a foundation for a new pipeline for orphan neurological disorders in the past year.
At Aurinia, the new CEO will shift gears to ophthalmology and immunology as the Canadian biotech launches an ambitious challenge to Allergan’s best-selling dry eye drug Restasis. In a Phase II head-to-head read out weeks ago, Aurinia’s voclosporin demonstrated a statistically significant improvement on efficacy compared to Restasis — a surprising win on a secondary endpoint. The primary endpoint of beating the blockbuster drug’s tolerability score was not met.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.